Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.56 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
| ▸ | CDK7 | P50613 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | GSK3B | P49841 | 3/20 | 0.50 |
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 2/20 | 0.49 |
| ▸ | CLK3 | P49761 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27982254 | 0.84 | BCAT2 (0.55) | RAB9AKMT2ANPC1BCAT2CDK7 | |
| SCHEMBL485966 | 0.80 | CTSA (0.53) | RAB9AKMT2ANPC1FKBP5BCAT2 | |
| SCHEMBL662433 | 0.79 | SMN1; SMN2 (0.67) | RAB9AKMT2ANPC1MAPTNAMPT | |
| SCHEMBL485959 | 0.79 | NPC1 (0.62) | RAB9AKMT2ANPC1BCAT2MAPT | |
| SCHEMBL19087072 | 0.79 | BCAT2 (0.63) | RAB9AKMT2ANPC1BCAT2MAPT | |
| SCHEMBL485750 | 0.79 | MAPT (0.50) | RAB9ANPC1BCAT2CDK7MAPT | |
| SCHEMBL22191704 | 0.78 | CDK7 (0.57) | CDK7MAPTGSK3BCLK2CLK3 | |
| SCHEMBL16913981 | 0.77 | PIK3C3 (0.62) | MAPTGSK3B | |
| SCHEMBL28622654 | 0.77 | RAB9A (0.93) | RAB9AKMT2ANPC1FKBP5MAPT | |
| SCHEMBL485794 | 0.76 | KCNK3 (0.61) | RAB9AKMT2ANPC1MAPTGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411363-B1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| EP-2411363-B1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150183773-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-20150183773-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-8987248-B2 | Substituted piperidines as Par-1 antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987248-B2 | Substituted piperidines as Par-1 antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2411363-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | Bayer Pharma AG (DE) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010108608-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010108608-A1 | SUBSTITUTED PIPERIDINES AS PAR-1 ANTAGONISTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183773-A1 | Substituted piperidines | VHL, PIR, PIGO | RAB9A 2471/4885KMT2A 3411/4885NPC1 168/4885 |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | F2R, F2RL1, F2RL3 | RAB9A 1333/4885KMT2A 2409/4885NPC1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.